Sunshine Biopharma, Inc.
SBFM
$1.05
$0.021.94%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 0.80% | 26.21% | -258.24% | 8.10% | -72.66% |
| Total Depreciation and Amortization | 50.76% | 48.92% | 42.44% | 52.11% | 54.25% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -- | -- | -- | -- | -100.00% |
| Change in Net Operating Assets | 121.66% | -121.49% | 84.60% | 69.38% | 11.47% |
| Cash from Operations | 52.54% | 46.35% | 72.18% | 46.19% | -26.61% |
| Capital Expenditure | 100.97% | 98.45% | 83.58% | 88.08% | -126.83% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -954.17% | 21.55% | -176.75% | 72.19% | 100.74% |
| Cash from Investing | 48.67% | 82.36% | 9.30% | 73.68% | 63.67% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | 29.73% | -104.20% | 41.89% | -- |
| Issuance of Common Stock | -55.23% | -100.00% | -- | -95.85% | 70,256.52% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -55.23% | -96.14% | 12,723.08% | -93.74% | 5,405.57% |
| Foreign Exchange rate Adjustments | 219.41% | -129.56% | 143.15% | 97.47% | -245.84% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 92.73% | -242.92% | 136.80% | -236.78% | 1.32% |